Detection of human survival motor neuron (SMN) protein in mice containing the SMN2 transgene: Applicability to preclinical therapy development for spinal muscular atrophy

Journal of Neuroscience Methods

Volumn 175, Issue 1, 2008, Pages 36-43

  Mattis, Virginia B ^a   Butchbach, Matthew E R ^b   Lorson, Christian L ^a  

^a UNIVERSITY OF MISSOURI   (United States)

^b THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Biomarker; Gem; Monoclonal antibody; Motor neuron disease; Spinal muscular atrophy; Survival motor neuron; Transgenic mouse

Indexed keywords

HYDROXYUREA; SURVIVAL MOTOR NEURON PROTEIN; VALPROIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY LABELING; ANTIBODY PRODUCTION; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FIBROBLAST; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPINAL MUSCULAR ATROPHY; TRANSGENE; WESTERN BLOTTING;

ALTERNATIVE SPLICING; AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, MONOCLONAL; CELLS, CULTURED; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; EPITOPE MAPPING; FIBROBLASTS; GENE EXPRESSION REGULATION; HUMANS; HYDROXYUREA; INDOLES; MICE; MICE, TRANSGENIC; MUSCULAR ATROPHY, SPINAL; SMN COMPLEX PROTEINS; SPINAL CORD; VALPROIC ACID;

EID: 52049085755     PISSN: 01650270     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneumeth.2008.07.024     Document Type: Article

References (40)

1. Andreassi C., Angelozzi C., Tiziano F.D., Vitali T., De Vincenzi E., Boninsegna A., et al. Phenylbutyrate increases SMN expression in vitro: relevance for treatment of spinal muscular atrophy. Eur J Hum Genet 12 (2004) 59-65
2. Andreassi C., Jarecki J., Zhou J., Coovert D.D., Monani U.R., Chen X., et al. Aclarubicin treatment restores SMN levels to cells derived from type I spinal muscular atrophy patients. Hum Mol Genet 10 (2001) 2841-2849
3. Avila A.M., Burnett B.G., Taye A.A., Gabanella F., Knight M.A., Hartenstein P., et al. Trichostatin A increases SMN expression and survival in a mouse model of spinal muscular atrophy. J Clin Invest 117 (2007) 659-671
4. Baron-Delage S., Abadie A., Echaniz-Laguna A., Melki J., and Beretta L. Interferons and IRF-1 induce expression of the survival motor neuron (SMN) genes. Mol Med 6 (2000) 957-968
5. Brichta L., Hofmann Y., Hahnen E., Siebzehnrubl F.A., Raschke H., Blumcke I., et al. Valproic acid increases the SMN2 protein level: a well-known drug as a potential therapy for spinal muscular atrophy. Hum Mol Genet 12 (2003) 2481-2489
6. Butchbach M.E.R., and Burghes A.H.M. Perspectives on models of spinal muscular atrophy for drug discovery. Drug Discov Today Dis Models 1 (2004) 151-156
7. Butchbach M.E.R., Edwards J.D., and Burghes A.H.M. Abnormal motor phenotype in the SMNDelta7 mouse model of spinal muscular atrophy. Neurobiol Dis 27 (2007) 207-219
8. Butchbach M.E.R., Edwards J.D., Schussler K.R., and Burghes A.H.M. A novel method for oral delivery of drug compounds to the neonatal SMNDelta7 mouse model of spinal muscular atrophy. J Neurosci Methods 161 (2007) 285-290
9. Butchbach M.E.R., Simard L.R., and Burghes A.H.M. SMN-independent amelioration of mouse spinal muscular atrophy by butyrate prodrugs. Soc Neurosci 338.7 (2005) [Abstract Viewer/Itinerary Planner]
10. Chang J.G., Hsieh-Li H.M., Jong Y.J., Wang N.M., Tsai C.H., and Li H. Treatment of spinal muscular atrophy by sodium butyrate. Proc Natl Acad Sci USA 98 (2001) 9808-9813
11. Coovert D.D., Le T.T., McAndrew P.E., Strasswimmer J., Crawford T.O., Mendell J.R., et al. The survival motor neuron protein in spinal muscular atrophy. Hum Mol Genet 6 (1997) 1205-1214
12. Crawford T.O., and Pardo C.A. The neurobiology of childhood spinal muscular atrophy. Neurobiol Dis 3 (1996) 97-110
13. Feldkotter M., Schwarzer V., Wirth R., Wienker T.F., and Wirth B. Quantitative analyses of SMN1 and SMN2 based on real-time lightCycler PCR: fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy. Am J Hum Genet 70 (2002) 358-368
14. Grzeschik S.M., Ganta M., Prior T.W., Heavlin W.D., and Wang C.H. Hydroxyurea enhances SMN2 gene expression in spinal muscular atrophy cells. Ann Neurol 58 (2005) 194-202
15. Hahnen E., Eyupoglu I.Y., Brichta L., Haastert K., Trankle C., Siebzehnrubl F.A., et al. In vitro and ex vivo evaluation of second-generation histone deacetylase inhibitors for the treatment of spinal muscular atrophy. J Neurochem 98 (2006) 193-202
16. Harlow E., and Lane D. Antibodies: A Laboratory Manual (1983), Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
17. Jarecki J., Chen X., Bernardino A., Coovert D.D., Whitney M., Burghes A.H.M., et al. Diverse small-molecule modulators of SMN expression found by high-throughput compound screening: early leads towards a therapeutic for spinal muscular atrophy. Hum Mol Genet 14 (2005) 2003-2018
18. Le T.T., Pham L.T., Butchbach M.E.R., Zhang H.L., Monani U.R., Coovert D.D., et al. SMNDelta7, the major product of the centromeric survival motor neuron (SMN2) gene, extends survival in mice with spinal muscular atrophy and associates with full-length SMN. Hum Mol Genet 14 (2005) 845-857
19. Lefebvre S., Burglen L., Reboullet S., Clermont O., Burlet P., Viollet L., et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell 80 (1995) 155-165
20. Lefebvre S., Burlet P., Liu Q., Bertrandy S., Clermont O., Munnich A., et al. Correlation between severity and SMN protein level in spinal muscular atrophy. Nat Genet 16 (1997) 265-269
21. Lorson C.L., Hahnen E., Androphy E.J., and Wirth B. A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy. Proc Natl Acad Sci USA 96 (1999) 6307-6311
22. Lunn M.R., Root D.E., Martino A.M., Flaherty S.P., Kelley B.P., Coovert D.D., et al. Indoprofen upregulates the survival motor neuron protein through a cyclooxygenase-independent mechanism. Chem Biol 11 (2004) 1489-1493
23. Majumder S., Varadharaj S., Ghoshal K., Monani U., Burghes A.H., and Jacob S.T. Identification of a novel cyclic AMP-response element (CRE-II) and the role of CREB-1 in the cAMP-induced expression of the survival motor neuron (SMN) gene. J Biol Chem 279 (2004) 14803-14811
24. Mattis V.B., Rai R., Wang J., Chang C.W., Coady T., and Lorson C.L. Novel aminoglycosides increase SMN levels in spinal muscular atrophy fibroblasts. Hum Genet (2006)
25. McAndrew P.E., Parsons D.W., Simard L.R., Rochette C., Ray P.N., Mendell J.R., et al. Identification of proximal spinal muscular atrophy carriers and patients by analysis of SMNT and SMNC gene copy number. Am J Hum Genet 60 (1997) 1411-1422
26. Monani U.R. Spinal muscular atrophy: a deficiency in a ubiquitous protein; a motor neuron-specific disease. Neuron 48 (2005) 885-896
27. Monani U.R., Coovert D.D., and Burghes A.H.M. Animal models of spinal muscular atrophy. Hum Mol Genet 9 (2000) 2451-2457
28. Monani U.R., Sendtner M., Coovert D.D., Parsons D.W., Andreassi C., Le T.T., et al. The human centromeric survival motor neuron gene (SMN2) rescues embryonic lethality in Smn(-/-) mice and results in a mouse with spinal muscular atrophy. Hum Mol Genet 9 (2000) 333-339
29. Monani U.R., Lorson C.L., Parsons D.W., Prior T.W., Androphy E.J., Burghes A.H.M., et al. A single nucleotide difference that alters splicing patterns distinguishes the SMA gene SMN1 from the copy gene SMN2. Hum Mol Genet 8 (1999) 1177-1183
30. Monani U.R., Pastore M.T., Gavrilina T.O., Jablonka S., Le T.T., Andreassi C., et al. A transgene carrying an A2G missense mutation in the SMN gene modulates phenotypic severity in mice with severe (type I) spinal muscular atrophy. J Cell Biol 160 (2003) 41-52
31. Munsat T.L., and Davies K.E. International SMA consortium meeting (June 26-28, 1992, Bonn, Germany). Neuromuscul Disord 2 (1992) 423-428
32. Novoyatleva T., Heinrich B., Tang Y., Benderska N., Butchbach M.E.R., Lorson C.L., et al. Protein phosphatase 1 binds to the RNA recognition motif of several splicing factors and regulates alternative pre-mRNA processing. Hum Mol Genet 17 (2008) 52-70
33. Riessland M., Brichta L., Hahnen E., and Wirth B. The benzamide M344, a novel histone deacetylase inhibitor, significantly increases SMN2 RNA/protein levels in spinal muscular atrophy cells. Hum Genet 120 (2006) 101-110
34. Sakla M.S., and Lorson C.L. Induction of full-length survival motor neuron by polyphenol botanical compounds. Hum Genet 122 (2008) 635-643
35. Schmid A., and DiDonato C.J. Animal models of spinal muscular atrophy. J Child Neurol 22 (2007) 1004-1012
36. Schrank B., Gotz R., Gunnersen J.M., Ure J.M., Toyka K.V., Smith A.G., et al. Inactivation of the survival motor neuron gene, a candidate gene for human spinal muscular atrophy, leads to massive cell death in early mouse embryos. Proc Natl Acad Sci USA 94 (1997) 9920-9925
37. Sumner C.J., Huynh T.N., Markowitz J.A., Perhac J.S., Hill B., Coovert D.D., et al. Valproic acid increases SMN levels in spinal muscular atrophy patient cells. Ann Neurol 54 (2003) 647-654
38. Thurmond J., Butchbach M.E.R., Palomo M., Pease B., Rao M., Bedell L., et al. Synthesis and biological evaluation of novel 2,4-diaminoquinazoline derivatives as SMN2 promoter activators for the potential treatment of spinal muscular atrophy. J Med Chem 51 (2008) 449-469
39. Wolstencroft E.C., Mattis V., Bajer A.A., Young P.J., and Lorson C.L. A non-sequence-specific requirement for SMN protein activity: the role of aminoglycosides in inducing elevated SMN protein levels. Hum Mol Genet 14 (2005) 1199-1210
40. Zhang M.L., Lorson C.L., Androphy E.J., and Zhou J. An in vivo reporter system for measuring increased inclusion of exon 7 in SMN2 mRNA: potential therapy of SMA. Gene Ther 8 (2001) 1532-1538